Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cusatuzumab · ARGX-110

Monoclonal antibody · Modulator of CD70 · developed by OncoVerity

Phase 1 Most advanced trial
1 Registered trials

What is Cusatuzumab?

Cusatuzumab is a defucosylated, humanized IgG1 monoclonal antibody that binds the extracellular domain of CD70, the ligand for the costimulatory receptor CD27, and neutralizes its activity. It may also induce antibody-dependent cellular cytotoxicity against CD70-expressing tumor cells. It is being studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ARGX-110, JNJ-74494550
Drug type
Monoclonal antibody
Targets
CD70
Mechanism
Modulator of CD70
Pathways
antibody-dependent cellular cytotoxicity, CD27 costimulatory signaling
Therapy area
Oncology
Developer
OncoVerity, Inc.
In trials of
ARGX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
RR5U4UFJ8L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04150887 Phase 1 Leukemia, Myeloid, Acute Active not recruiting ARGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leukemia, Myeloid, Acute

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.